Hyderabad :
Dr. Reddy’s Laboratories Limited, a renowned global pharmaceutical company, has introduced the drug-free, non-invasive migraine management wearable device, Nerivio, in Germany through its subsidiary, betapharm, marking its foray into digital therapeutics in Europe.
Nerivio, approved by the United States Food and Drug Administration (USFDA) and CE-mark certified in Europe, was initially unveiled by Dr Reddy’s at the DGN Kongress organized by the German Association of Neurology in Berlin and showcased at the 17th European Headache Congress held in Barcelona, Spain, in 2023, a company statement said on Wednesday.
The Neurological Association of South Africa’s annual congress on April 17, 2024, will witness the presentation and launch of Nerivio, graced by the presence of Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine ? Dartmouth, and Vice President of the New England Institute for Neurology and Headache. Furthermore, Nerivio will be featured at the International Headache Society 2024 iHEAD meeting in Berlin, Germany, in May 2024. Subsequently, Dr. Reddy’s plans to introduce Nerivio in Spain and the UK.
In a significant move last year, Dr Reddy’s entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company, for the marketing and distribution of Nerivio across multiple markets.
Migraine poses a significant global health challenge, affecting approximately 30 percent of adults on 15 or more days per month, with a prevalence estimated at 14?15 percent globally. Notably, migraine disproportionately impacts women, with approximately 8 to 10 million people affected in Germany alone, comprising 14.8 percent of women and 6.0 percent of men. In India, where approximately 213 million individuals suffer from migraines, women constitute around 60 percent of the affected population.
Dr Reddy’s initially launched Nerivio in India in 2023, accompanied by the unique patient support program ‘M-Free.’ This comprehensive program offers a range of services, including patient onboarding and counselling, device demonstrations, doorstep delivery, flexible payment options, informative content, and dedicated customer care. Additionally, the M-Free awareness program promotes lifestyle modifications through services such as nutritionist consultations, yoga, and meditation sessions, facilitating holistic migraine management.
M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) at Dr Reddy’s, expressed optimism about Nerivio’s expansion into identified markets, emphasizing its potential to address unmet clinical needs among migraine patients and reduce pill burden. Ramana underscored the significance of digital therapeutics in providing relief to migraine sufferers, particularly during the childbearing age, and looked forward to feedback from patients and healthcare professionals in the new markets
